Volume | 1,240,104 |
|
|||||
News | - | ||||||
Day High | 0.43 | Low High |
|||||
Day Low | 0.3625 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Trevena Inc | TRVN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.4225 | 0.3625 | 0.43 | 0.366 | 0.402 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,329 | 1,240,104 | $ 0.3890051 | $ 482,407 | - | 0.3302 - 3.28 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:21:44 | formt | 628 | $ 0.3536 | USD |
Trevena Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.78M | 18.32M | - | 3.13M | -40.29M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Trevena News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.4098 | 0.43 | 0.3625 | 0.400831 | 780,293 | -0.0562 | -13.71% |
1 Month | 0.521 | 0.541 | 0.3302 | 0.4081242 | 326,115 | -0.1674 | -32.13% |
3 Months | 0.67 | 0.70 | 0.3302 | 0.4821794 | 186,526 | -0.3164 | -47.22% |
6 Months | 0.6275 | 0.7693 | 0.3302 | 0.5468681 | 151,710 | -0.2739 | -43.65% |
1 Year | 0.76 | 3.28 | 0.3302 | 1.97 | 994,512 | -0.4064 | -53.47% |
3 Years | 45.375 | 55.00 | 0.3302 | 17.68 | 1,165,846 | -45.02 | -99.22% |
5 Years | 36.25 | 112.50 | 0.3302 | 40.15 | 1,940,415 | -35.90 | -99.02% |
Trevena Description
Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain. |